



Sir:

PATENT Customer No. 22,852 Attorney Docket No. 09487.0003-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	
John Devane) Group Art Unit: 1614
Application No.: 10/798,421) Examiner: Unassigned
Filed: March 12, 2004))
For: TREATMENT OF INTESTINAL CONDITIONS WITH N-2,3,3-TETRAMETHYLBICYCLO[2.2.1]HEPTAN-2-AMINE) Confirmation No.: 6571))
Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicant brings to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents, including any copending patent applications, are attached.

Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

Application No. 10/798,421 Attorney Docket No. 09487.0003-00

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicant determines that the cited documents do not constitute "prior art" under United States law, Applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated: August 19, 2004

Michele C. Bosch Reg. No. 40,524

INFORMATION DISCLOSURE CITATION

Atty. Docket No.	09487.0003-00		Appln. No.	10/798,421	
Applicant	John Devane	AUG 1 9 2004	25		
Filing Date	March 12, 2004	THE OFF	Group:	1614	
		ADEMARIA			

U.S. PATENT DOCUMENTS						
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
						······································

FOREIGN PATENT DOCUMENTS						
	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
	WO 00/33812	6/15/2000	PCT			
	WO 00/35280	6/22/2000	PCT			
	WO 00/35279	6/22/2000	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
Mangel, "Potentiation of Colonic Contractility to Cholecystokinin and Other Peptides," <i>European Journal Of Pharmacology</i> , 100 (1984) pgs. 285-290				
Braida, et al., "Excitatory and Inhibitory Effects of Second-Generation Cholinesterase Inhibitors on Rat Gastrointestinal Transit," <i>Pharmacological Research</i> , Vol. 41, No. 6, (2000) pgs. 671-677				

Examiner	Date Considered			
*Examiner:	through citation is	if reference considered, whether or not citation is in conformance with MPEP 609; draw line gh citation if not in conformance and not considered. Include copy of this form with next nunication to applicant.		
Form PTO 14	149	Patent and Trademark Office - U.S. Department of Commerce		